Dynamic Changes of Ductus Arteriosus in < 31 Weeks Preterm Infants: an Observational Study

NCT ID: NCT06950164

Last Updated: 2025-04-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-04-01

Study Completion Date

2026-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The ductus arteriosus quickly closes itself. is an important channel connecting the maternal fetal circulation before birth. After birth, this ductus arteriosus generally no longer has a physical function, so ductus arteriosus quickly closes itself. The persistent presence of ductus arteriosus leads to significant pressure changes in the systemic and pulmonary circulation, which have adverse effects on extremely/very premature infants. Therefore, persistent patent ductus arteriosus (PDA) is a systemic disease.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

hemodynamic significant PDA(hsPDA) is a risk factor for intraventricular hemorrhage(IVH), bronchopulmonary dysplasia(BPD), necrotizing enterocolitis(NEC). A meta-analysis from Cochrane shows that compared to conservative treatment, drug therapy for PDA within 3 and 7 days after birth does not promote PDA closure and reduce the incidence of BPD. Therefore, there is currently a tendency not to provide medication intervention. Although ductus arteriosus quickly closes itself after birth in normal term infants, however, the dynamic changes detail of ductus arteriosus in preterm infants are unknown.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Preterm Ductus Arteriosus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

observation group

in the group, no intervention was given, and the preterm infants were diagnosed with respiratory distress syndrome(RDS)

observation group

Intervention Type OTHER

in the group, no intervention was given, and the preterm infants were diagnosed with respiratory distress syndrome(RDS)

control group

in the group, no intervention was given, but the preterm infants were diagnosed without respiratory distress syndrome(RDS)

control group

Intervention Type OTHER

in the group, no intervention was given, but the preterm infants were diagnosed without respiratory distress syndrome(RDS)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

observation group

in the group, no intervention was given, and the preterm infants were diagnosed with respiratory distress syndrome(RDS)

Intervention Type OTHER

control group

in the group, no intervention was given, but the preterm infants were diagnosed without respiratory distress syndrome(RDS)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* less than 32 weeks' gestational age
* admission with 1 hours after birth

Exclusion Criteria

* congenital abnormalities
* parents' refusal
Minimum Eligible Age

1 Minute

Maximum Eligible Age

1 Hour

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Chongqing Medical Center for Women and Children

OTHER

Sponsor Role collaborator

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Chen Long,MD

director

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Women and Children's hospital of Chonqing Medical University

Chongqing, Chongqing Municipality, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ductus arteriosus

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.